Table 2 Direct comparison for COR, TC, fatigue, hot flush and BCS.

From: Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer

 

Outcome

Events

Total

Events

Total

OR (95% CI)

Let vs. Exe (<20wks)

COR

112

155

91

148

1.63 (1.01 to 2.64)

 

TC

149

155

136

148

2.09 (0.79 to 5.54)

 

Fatigue

14

155

11

148

1.23 (0.54 to 2.81)

 

Hot flush

43

155

22

148

2.47 (1.30 to 4.70)

 

BCS

11

127

17

124

0.60 (0.27 to 1.33)

Let vs. Exe (<20wks)+Cel

COR

17

28

18

30

1.03 (0.36 to 2.95)

 

TC

28

28

29

30

2.90 (0.11 to 74.13)

 

Fatigue

4

28

3

30

1.50 (0.30 to 7.39)

 

Hot flush

19

28

6

30

8.44 (2.55 to 27.91)

 

BCS

Let vs. Let+Eve

COR

78

132

94

138

0.68 (0.41 to 1.11)

 

TC

90

132

112

138

0.50 (0.28 to 0.87)

 

Fatigue

6

132

17

138

0.34 (0.13 to 0.89)

 

Hot flush

22

132

15

138

1.64 (0.81 to 3.32)

 

BCS

Let vs. CT

COR

20

22

17

22

2.94 (0.50 to 17.14)

 

TC

20

22

20

22

1.00 (0.13 to 7.81)

 

Fatigue

10

22

7

22

1.79 (0.52 to 6.10)

 

Hot flush

9

22

2

22

6.92 (1.29 to 37.29)

 

BCS

4

22

1

22

4.67 (0.48 to 45.62)

Let vs. Tam

COR

85

154

61

170

2.20 (1.41 to 3.44)

 

TC

153

154

169

170

0.91 (0.06 to 14.60)

 

Fatigue

8

154

8

170

1.11 (0.41 to 3.03)

 

Hot flush

31

154

41

170

0.79 (0.47 to 1.34)

 

BCS

69

154

60

170

1.49 (0.95 to 2.33)

Let vs. Ana

COR

95

127

85

123

1.33 (0.76 to 2.31)

 

TC

121

127

114

123

1.59(0.55 to 4.61)

 

Fatigue

10

127

9

123

1.08 (0.42 to 2.76)

 

Hot flush

24

127

18

123

1.36 (0.70 to 2.65)

 

BCS

11

127

24

123

0.39 (0.18 to 0.84)

Ana vs. Ana+Gef

COR

48

79

52

109

1.70 (0.94 to 3.05)

 

TC

74

85

95

121

1.84 (0.85 to 3.97)

 

Fatigue

8

85

5

121

2.41 (0.76 to 7.64)

 

Hot flush

11

85

7

121

2.42 (0.90 to 6.53)

 

BCS

27

85

51

121

0.64 (0.36 to 1.14)

Ana vs. Ana+Tam

COR

42

113

43

109

0.91 (0.53 to 1.56)

 

TC

106

113

100

109

1.36 (0.49 to 3.80)

 

Fatigue

6

113

8

109

0.71 (0.24 to 2.11)

 

Hot flush

20

113

30

109

0.57 (0.30 to 1.07)

 

BCS

21

113

11

109

2.03 (0.93 to 4.45)

 

Outcome

Events

Total

Events

Total

OR (95% CI)

Ana vs. Tam

COR

123

276

99

259

1.30 (0.92 to 1.83)

 

TC

308

341

302

331

0.89 (0.53 to 1.51)

 

Fatigue

11

341

22

331

0.47 (0.22 to 0.98)

 

Hot flush

39

341

44

331

0.84 (0.53 to 1.33)

 

BCS

82

255

45

228

1.95 (1.26 to 3.02)

Ana vs. Exe (<20wks)

COR

85

123

78

124

1.32 (0.78 to 2.24)

 

TC

114

123

114

124

1.11 (0.44 to 2.84)

 

Fatigue

9

123

10

124

0.90 (0.35 to 2.30)

 

Hot flush

18

123

10

124

1.95 (0.86 to 4.42)

 

BCS

24

123

17

124

1.53 (0.77 to 3.01)

Tam vs. Tam+Ana

COR

39

108

43

109

0.87 (0.50 to 1.50)

 

TC

101

108

100

109

1.30 (0.47 to 3.62)

 

Fatigue

8

108

8

109

1.01 (0.36 to 2.80)

 

Hot flush

28

108

30

109

0.92 (0.51 to 1.68)

 

BCS

8

108

11

109

0.71 (0.27 to 1.85)

Exe (<20wks) vs. Exe (≥20wks)

COR

11

26

12

25

0.79 (0.26 to 2.40)

 

TC

26

26

25

26

3.12 (0.12 to 80.12)

 

Fatigue

26

25

 

Hot flush

26

25

 

BCS

4

26

1

25

4.36 (0.45 to 42.08)

Exe (<20wks) vs.Exe (<20wks)+Cel

COR

13

24

18

30

0.79 (0.27 to 2.33)

 

TC

22

24

29

30

0.38 (0.03 to 4.46)

 

Fatigue

1

24

3

30

0.39 (0.04 to 4.02)

 

Hot flush

12

24

6

30

4.00 (1.20 to 13.28)

 

BCS

  1. CT = chemotherapy, Ana = anastrozole, Tam = tamoxifen, Gef = gefitinib, Let = letrozole, Exe(<20wks) = Exemestane (<20wks), Exe (≥20wks) = Exemestane (≥20wks), Cel = Celecoxib, Eve = Everolimus.